RT info:eu-repo/semantics/article
T1 Saccharomyces cerevisiae Fungemia: An Emerging Infectious Disease
A1 Muñoz, Patricia
A1 Bouza, Emilio
A1 Cuenca Estrella, Manuel
A1 Eiros Bouza, José María
A1 Pérez, María Jesús
A1 Sanchez Somolinos, Mar
A1 Rincon, Cristina
A1 Hortal, Javier
A1 Peláez, Teresa
K1 Enfermedad infecciosa
K1 Fungemia
K1 32 Ciencias Médicas
AB Background: Saccharomyces cerevisiae is well known in the baking and brewing industry and is also used asa probiotic in humans. However, it is a very uncommon cause of infection in humans.Methods: During the period of 15–30 April 2003, we found 3 patients with S. cerevisiae fungemia in anintensive care unit (ICU). An epidemiological study was performed, and the medical records for all patients whowere in the unit during the second half of April were assessed.Results: The only identified risk factor for S. cerevisiae infection was treatment with a probiotic containingSaccharomyces boulardii (Ultralevura; Bristol-Myers Squibb). This probiotic is used in Europe for the treatmentand prevention of Clostridium difficile–associated diarrhea. The 3 patients received the product via nasograstrictube for a mean duration of 8.5 days before the culture result was positive, whereas only 2 of 41 control subjectshad received it. Surveillance cultures for the control patients admitted at the same time did not reveal any carriersof the yeast. Strains from the probiotic capsules and the clinical isolates were identified as S. cerevisiae, with identicalDNA fingerprinting. Discontinuation of use of the product in the unit stopped the outbreak of infection. A reviewof the literature identified another 57 cases of S. cerevisiae fungemia. Overall, 60% of these patients were in theICU, and 71% were receiving enteral or parenteral nutrition. Use of probiotics was detected in 26 patients, and17 patients died.Conclusions: Use of S. cerevisiae probiotics should be carefully reassessed, particularly in immunosuppressedor critically ill patients.
PB Oxford University Press
SN 1058-4838
YR 2005
FD 2005
LK http://uvadoc.uva.es/handle/10324/45592
UL http://uvadoc.uva.es/handle/10324/45592
LA eng
NO Clinical Infectious Diseases,2005, vol. 40, n.11, p. 1625-1634
NO Producción Científica
DS UVaDOC
RD 18-nov-2024